0001567619-20-013325.txt : 20200715 0001567619-20-013325.hdr.sgml : 20200715 20200715213223 ACCESSION NUMBER: 0001567619-20-013325 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200430 FILED AS OF DATE: 20200715 DATE AS OF CHANGE: 20200715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FUCHS HENRY J CENTRAL INDEX KEY: 0001197355 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 201030578 MAIL ADDRESS: STREET 1: C/O BIOMARIN PHARMACEUTICAL INC. STREET 2: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2020-04-30 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001197355 FUCHS HENRY J C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 0 1 0 0 President, Worldwide R&D Common Stock 2020-04-30 5 A 0 339 62.586 A 102995 D Common Stock 2020-07-13 4 M 0 224 67.81 A 103219 D Common Stock 2020-07-13 4 M 0 13810 67.81 A 117029 D Common Stock 2020-07-13 4 M 0 8977 63.10 A 126006 D Common Stock 2020-07-13 4 S 0 23011 130.00 D 102995 D Stock Option (Right to buy Common Stock) 67.810 2020-07-13 4 M 0 224 0 D 2017-01-15 2023-05-14 Common Stock 224 1250 D Stock Option (Right to buy Common Stock) 67.81 2020-07-13 4 M 0 13810 0 D 2013-11-15 2023-05-14 Common Stock 13810 75716 D Stock Option (Right to buy Common Stock) 63.10 2020-07-13 4 M 0 8977 0 D 2014-12-04 2024-06-03 Common Stock 8977 49423 D Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.025. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2020-07-15